GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India
· Delayed Price · Currency is INR | Market Cap | 430.82B |
| Revenue (ttm) | 37.09B |
| Net Income (ttm) | 9.55B |
| Shares Out | 169.41M |
| EPS (ttm) | 56.38 |
| PE Ratio | 45.10 |
| Forward PE | 39.81 |
| Dividend | 42.00 (1.67%) |
| Ex-Dividend Date | n/a |
| Volume | 2,717 |
| Average Volume | 2,464 |
| Open | 2,500.75 |
| Previous Close | 2,520.20 |
| Day's Range | 2,496.30 - 2,537.00 |
| 52-Week Range | 1,924.30 - 3,515.95 |
| Beta | -0.02 |
| RSI | 48.54 |
| Earnings Date | Feb 6, 2026 |
About BOM:500660
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;... [Read more]
Financial Performance
In 2024, BOM:500660's revenue was 37.49 billion, an increase of 8.56% compared to the previous year's 34.54 billion. Earnings were 9.28 billion, an increase of 57.23%.
Financial StatementsNews
GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q2 2026 Earnings Call Highlights: Navigating ...
GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q2 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Q2 2026 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Pharma stocks rally: Glaxo surges 7%, Torrent gains after Q4; Gland steady post mixed results
Pharma stocks were trading firmly in the green on Tuesday morning, with GlaxoSmithKline Pharmaceuticals leading the charge—rising 7.4% to ₹2,992.80 as of 10:05 AM. The broader sector saw widespread bu...
GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q3 2025 Earnings Call Highlights: Strong ...
GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
Q3 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Q3 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
GSK Pharma sets record date for Rs 12 special interim dividend on November 7, 2024
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has announced the record date for its special interim dividend, set for November 7, 2024. This follows the company’s earlier declaration on October...